Dry eye solution moves into Phase III

Article

Prolacria (diquafosol tetrasodium ophthalmic solution) 2% has entered a Phase III trial for the treatment of dry eye disease, according to an announcement from the solution's developer, Inspire Pharmaceuticals, Inc.

Prolacria (diquafosol tetrasodium ophthalmic solution) 2% has entered a Phase III trial for the treatment of dry eye disease, according to an announcement from the solution's developer, Inspire Pharmaceuticals, Inc. The design of the trial was agreed between Inspire and the FDA under a Special Protocol Assessment (SPA).

The randomized, placebo-controlled, multicentre environmental trial, which will assess safety and efficacy, has now begun enrolling the first of a planned 450 study subjects. Subjects will receive either Prolacria, a P2Y2 receptor agonist, or placebo eye drops four times daily for six weeks. A criterion for inclusion in the trial is a fluorescein staining score of three in the central cornea, and the primary efficacy endpoint is a score of zero at six weeks.

In 2005, the FDA had requested further information on Prolacria, following a statement regarding a possible recommendation by the US Securities and Exchange Commission (SEC) that a lawsuit - relating to possible fraudulent violations involving the use of manipulative and deceptive devices in late stage trial data - be brought against Inspire CEO Christy L. Shaffer and Mary B. Bennett, Inspire's executive vice president of operations and communications. Therefore, under the current SPA, any positive results in terms of efficacy in this trial will be considered in conjunction with previous Prolacria trial results, and the overall risk/benefit ratio.

Newsletter

Get the essential updates shaping the future of pharma manufacturing and compliance—subscribe today to Pharmaceutical Technology and never miss a breakthrough.

Recent Videos
Omer Trivizki, MD, MBA, a retina specialist from Tel Aviv Medical Center, speaks about VOY-101, a Novel, Complement-Modulating Gene Therapy for Geographic Atrophy at the American Society of Retina Specialists (ASRS) Annual Meeting
João Pedro Marques, MD, MSc, PhD discusses a retrospective study of 800 patients with inherited retinal diseases during the American Society of Retina Specialists (ASRS) annual meeting
Christine Curcio, PhD, of the University of Alabama at Birmingham Heersink School of Medicine, shares histology update and revised nomenclature for OCT with Sheryl Stevenson of the Eye Care Network and Ophthalmology Times
© 2025 MJH Life Sciences

All rights reserved.